CoChat
Sign Up
Cited by 27Treatment of Major DepressionBipolar Disorder and TreatmentPharmacovigilance and Adverse Drug Reactions

Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder

Montgomery, Stuart A., Fava, Maurizio, Padmanabhan, Sudharshan K., J. Guico-Pabia, Christine, Tourian, Karen A.·2009·International Clinical Psychopharmacology
DOI 10.1097/yic.0b013e32832fbb5a
Open this paper in CoChat — free account

Abstract

The objective of this study was to assess discontinuation symptoms with desvenlafaxine (administered as desvenlafaxine succinate) treatment for major depressive disorder. Data were analyzed from nine 8-week, double-blind (DB), placebo-controlled studies of desvenlafaxine (50, 100, 200, or 400 mg/day; placebo, n = 319; desvenlafaxine, n = 578) and a relapse-prevention study [12-week, open-label (OL) 200 or 400 mg/day desvenlafaxine (n = 373); 6-month DB placebo (n = 73) or desvenlafaxine (n = 118)]. Rates of taper/poststudy-emergent adverse events were summarized. Discontinuation-Emergent Signs and Symptoms (DESS) checklist scores were analyzed in treatment completers at the end of OL and DB treatment. The most common (> or = 5%) taper/poststudy-emergent adverse events among desvenlafaxine patients were dizziness, nausea, headache, irritability, diarrhea, anxiety, abnormal dreams, fatigue, and hyperhidrosis. In the short-term studies, the highest DESS scores observed for desvenlafaxine groups occurred at first assessment after discontinuation of all active treatment (1.9-5.7). Desvenlafaxine 50- and 100-mg/day groups had significantly increased scores versus placebo (P values < or = 0.028). DESS scores increased significantly for patients discontinuing 12-week, OL desvenlafaxine 200 and 400 mg/day doses compared with those continuing desvenlafaxine (P values < or = 0.022). After the 6-month DB phase, DESS scores increased significantly compared with placebo for patients discontinuing 400 mg/day only (P = 0.029). In conclusion, cessation of desvenlafaxine use is associated with discontinuation symptoms after both short-term and long-term treatment.

Integrity signals

Registry

Crossref · 10.1097/yic.0b013e32832fbb5a

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Montgomery, S. A., Fava, M., Padmanabhan, S. K., J. Guico-Pabia, C., & Tourian, K. A.
Affiliations
  • Imperial College London (GB)
  • Wyeth (US)
Corresponding author
Montgomery, Stuart A.
ORCID
Montgomery, Stuart A.
Venue
International Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2009-11
Volume
24
Issue
6
Pages
296-305
ISSN
0268-1315 (ISSN-L)
DOI
10.1097/yic.0b013e32832fbb5a
OpenAlex
W1999257848
Cited by
27
References
41
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 1
FWCI
1.44
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
desvenlafaxine, major depressive disorder, discontinuation symptoms, drug discontinuation, adverse events, antidepressant discontinuation, relapse prevention, dizziness, irritability, hyperhidrosis
MeSH terms
Desvenlafaxine Succinate, Adolescent, Adult, Aged, Aged, 80 and over, Antidepressive Agents, Clinical Trials as Topic, Cyclohexanols, Major Depressive Disorder, Depressive Disorder, Major, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Substance Withdrawal Syndrome, Time Factors, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review